id: NEW:aud_pharmacotherapy_utilization_to_alcohol_use_disorder
name: AUD Pharmacotherapy Utilization â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:aud_pharmacotherapy_utilization
  node_name: AUD Pharmacotherapy Utilization
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: FDA-approved pharmacotherapies (disulfiram, acamprosate, naltrexone) are available but under-utilized
  for AUD treatment'
- 'Step 2: Under-utilization limits patient access to effective medication-assisted treatment'
- 'Step 3: Lack of treatment options perpetuates AUD symptomatology and prevents recovery'
- 'Step 4: Improved pharmacotherapy utilization would reduce AUD prevalence and associated harms'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Malia A Belnap et al. 2024. "Endpoints for Pharmacotherapy Trials for Alcohol Use
    Disorder." https://doi.org/10.1007/s40290-024-00526-x
  supporting_citations:
  - US Food and Drug Administration approved medications for AUD (disulfiram, acamprosate, naltrexone)
    - referenced in abstract
  - World Health Organization (WHO) risk drinking level framework - referenced in abstract
  - National Institute on Alcohol Abuse and Alcoholism (NIAAA) definition of recovery - referenced in
    abstract
  doi: 10.1007/s40290-024-00526-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: This paper reviews endpoints for AUD pharmacotherapy trials, noting that currently approved
  medications are under-utilized. The shift from abstinence-only to harm-reduction endpoints and incorporation
  of biological markers and patient-oriented outcomes may improve pharmacotherapy development and utilization.
moderators:
- name: endpoint_type
  direction: strengthens
  strength: moderate
  description: Harm-reduction endpoints (WHO risk drinking level reductions) versus abstinence-based endpoints
    may improve treatment engagement and trial success
- name: outcome_measurement_method
  direction: strengthens
  strength: moderate
  description: Biological markers of alcohol use may provide more objective endpoints compared to patient
    self-report
structural_competency:
  equity_implications: 'The paper highlights a structural barrier in AUD treatment: the under-utilization
    of approved pharmacotherapies. This represents a healthcare system failure rather than individual
    patient failure. The emphasis on harm-reduction versus abstinence-only approaches represents a structural
    shift in treatment philosophy that may reduce barriers to care. Equity implications include the need
    for patient-centered outcomes and provider-patient relationship quality in treatment.'
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.149892'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
